Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics
Iterum Therapeutics (Nasdaq: ITRM) announced the presentation of a scientific poster at the 35th Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna, Austria, from April 11-15, 2025. The presentation, delivered by Dr. Sailaja Puttagunta on April 13, 2025, focused on the 'Impact of age on antibiotic resistance and efficacy of antibiotics for women with uncomplicated urinary tract infection (uUTI)'. The company, which specializes in developing next-generation oral and IV antibiotics for multi-drug resistant pathogens in both community and hospital settings, will make the poster available on their website under the Publications section.
Iterum Therapeutics (Nasdaq: ITRM) ha annunciato la presentazione di un poster scientifico al 35° Congresso Annuale Europeo di Microbiologia Clinica e Malattie Infettive (ECCMID) a Vienna, Austria, dal 11 al 15 aprile 2025. La presentazione, tenuta dalla Dr.ssa Sailaja Puttagunta il 13 aprile 2025, si è concentrata sull' 'Impatto dell'età sulla resistenza agli antibiotici e sull'efficacia degli antibiotici per le donne con infezione del tratto urinario non complicata (uUTI)'. L'azienda, specializzata nello sviluppo di antibiotici orali e IV di nuova generazione per patogeni multi-resistenti sia in contesti comunitari che ospedalieri, renderà disponibile il poster sul proprio sito web nella sezione Pubblicazioni.
Iterum Therapeutics (Nasdaq: ITRM) anunció la presentación de un póster científico en el 35° Congreso Anual Europeo de Microbiología Clínica y Enfermedades Infecciosas (ECCMID) en Viena, Austria, del 11 al 15 de abril de 2025. La presentación, realizada por la Dra. Sailaja Puttagunta el 13 de abril de 2025, se centró en el 'Impacto de la edad en la resistencia a los antibióticos y la eficacia de los antibióticos para mujeres con infección del tracto urinario no complicada (uUTI)'. La empresa, que se especializa en el desarrollo de antibióticos orales e IV de nueva generación para patógenos multirresistentes en entornos comunitarios y hospitalarios, hará disponible el póster en su sitio web en la sección de Publicaciones.
Iterum Therapeutics (Nasdaq: ITRM)은 2025년 4월 11일부터 15일까지 오스트리아 비엔나에서 열리는 제35회 유럽 임상 미생물학 및 감염병 학회(ECCMID)에서 과학 포스터를 발표한다고 발표했습니다. 2025년 4월 13일 Dr. Sailaja Puttagunta가 발표한 이 발표는 '여성의 단순한 요로 감염(uUTI)에 대한 항생제의 저항성과 효능에 대한 나이의 영향'에 초점을 맞추었습니다. 이 회사는 지역 사회 및 병원 환경에서 다제내성 병원체를 위한 차세대 경구 및 IV 항생제 개발을 전문으로 하며, 포스터는 자사의 웹사이트의 출판물 섹션에서 제공될 예정입니다.
Iterum Therapeutics (Nasdaq: ITRM) a annoncé la présentation d'une affiche scientifique lors du 35ème Congrès Annuel Européen de Microbiologie Clinique et de Maladies Infectieuses (ECCMID) à Vienne, en Autriche, du 11 au 15 avril 2025. La présentation, faite par Dr. Sailaja Puttagunta le 13 avril 2025, était axée sur l' 'Impact de l'âge sur la résistance aux antibiotiques et l'efficacité des antibiotiques pour les femmes atteintes d'infection urinaire non compliquée (uUTI)'. L'entreprise, spécialisée dans le développement d'antibiotiques oraux et IV de nouvelle génération pour les pathogènes multirésistants dans les milieux communautaires et hospitaliers, mettra l'affiche à disposition sur son site internet dans la section Publications.
Iterum Therapeutics (Nasdaq: ITRM) gab die Präsentation eines wissenschaftlichen Posters auf dem 35. Jahreskongress der Europäischen Gesellschaft für Klinische Mikrobiologie und Infektionskrankheiten (ECCMID) in Wien, Österreich, vom 11. bis 15. April 2025 bekannt. Die Präsentation, die am 13. April 2025 von Dr. Sailaja Puttagunta gehalten wurde, konzentrierte sich auf die 'Auswirkungen des Alters auf die Antibiotikaresistenz und die Wirksamkeit von Antibiotika bei Frauen mit unkomplizierter Harnwegsinfektion (uUTI)'. Das Unternehmen, das sich auf die Entwicklung von Antibiotika der nächsten Generation für multiresistente Erreger in Gemeinschafts- und Krankenhausumgebungen spezialisiert hat, wird das Poster auf seiner Website im Bereich Veröffentlichungen zur Verfügung stellen.
- None.
- None.
DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that one poster was presented at the 35th Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) held in Vienna, Austria, from April 11-15, 2025.
The poster presented at ECCMID was:
| Title: Impact of age on antibiotic resistance and efficacy of antibiotics for women with uncomplicated urinary tract infection (uUTI) Presenting Author: Sailaja Puttagunta, MD Date: April 13, 2025 | |
This Poster will be available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab.
About Iterum Therapeutics plc
Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit www.iterumtx.com.
About ORLYNVAH™
ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTI. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
FAQ
What was the main focus of Iterum Therapeutics' (ITRM) presentation at ECCMID 2025?
When and where did Iterum Therapeutics (ITRM) present their research at ECCMID 2025?
Who presented Iterum Therapeutics' (ITRM) research at ECCMID 2025?
Where can investors find Iterum Therapeutics' (ITRM) ECCMID 2025 poster presentation?
